DOCSLIB.ORG

Potential Targets of YDJ,ABAT,ABL1,ACADSB,ACOT13,ACOX1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Potential Targets of YDJ,ABAT,ABL1,ACADSB,ACOT13,ACOX1 potential targets of YDJ,ABAT,ABL1,ACADSB,ACOT13,ACOX1,ACRB,ACSL3,ACSL4,ACTB,ADH1B,ADH1C, ADH5,AHR,AKR1C1,AKR1C2,AKR1C3,AKR1D1,AKT1,ALDA,ALDH2,ALDH5A1,ALOX5, ANXA1,AR,ARF1,ARF6,ATP1A1,ATP1A2,ATP1A3,ATP5A1,ATP5B,ATP5C1,AURKB,BCL 2,BEVGP1,C8G,CACNA1C,CACNA1D,CACNA1F,CACNA1S,CACNB1,CACNB2,CACNB 3,CACNB4,CALM1,CAMC,CASP3,CASP8,CAT,CAT3,CBH,CBR1,CDK6,CEBPB,CES1,CH OB,CLEC4E,CNR1,CNR2,COX4I1,COX5A,COX5B,COX6A2,COX6B1,COX6C,COX7A1,C OX7B,COX7C,COX8A,CSNK2A1,CSNK2B,CTAC,CTAD,CTRB1,CUMD,CYC1,CYP102A1, CYP19A1,CYP1B1,CYP27B1,CYP2C8,CYPC,DBI,DHBE,DKFZP686P18130,DSBB,ECI2,E FTUD1,EIF3F,ELOVL4,ESR1,ESR2,ESRRA,ESRRB,ESRRG,FABB,FABF,FABG3,FABH,FABP 6,FABZ,FADR,FADS1,FADS2,FECH,FECH,FFAR1,FHUA,FKBP1A,FURIN,FUSA,G6PD,GA BRA1,GABRA2,GABRA3,GABRA4,GABRA5,GABRA6,GABRB1,GABRB2,GABRB3,GABR D,GABRE,GABRG1,GABRG2,GABRG3,GABRP,GABRQ,GAG,GAG- POL,GLRA3,GLTP,GM2A,GPBAR1,GPER1,GRIN1,GRIN2A,GRIN2B,GRIN2C,GRIN2D,G RIN3A,GRIN3B,GSTP1,GUCA1A,HAO1,HCK,HDAC2,HDAC9,HIBCH,HMGCR,HNF4A, HNF4G,HOXA10,HSD11B1,HSD11B2,HSD17B1,HSD17B11,HSD3B1,HSP90AA1,HSP A2,HUTH,IGHG1,IGHG2,IL1B,IL6,INS,ITGAL,ITGB2,JAK1,KANSL3,KSI,LALBA,LCN2,LC N9,LIP3,LIPB,LPL,LPXC,LSS,LTB4R,LTB4R2,LTF,LUXF,LY96,MB,MDLB,MIF,MNDD,MT- CO1,MT-CO2,MT-CO3,MT- CYB,MTTP,MVAA,NAHD,NCOA1,NCOA2,NCSA,NDUFV3,NEF,NFKB1,NFKB2,NPPB,N PRS,NQO2,NR1H4,NR1I2,NR1I3,NR3C1,NR3C2,NRDB,OGDH,OPRK1,PAB,PAC,PAEP, PCAG,PCAH,PETA,PETB,PETC,PGR,PIK3CG,PIM1,PKIA,PLA2G1B,PLA2G2A,PLA2G2D, PLA2G2E,PMP2,PPA_RS05235,PPARA,PPARD,PPARG,PPCA,PPP1CC,PPP3CA,PPP3R1, PPT1,PRKACA,PRLR,PTGS1,PTGS2,PTK2B,PUFC,PUFL,PUFM,PUHA,PVDQ,PVGP1,PYP, RCVRN,RHO,RORA,RUVBL2,RV1372,RXRA,RXRB,RXRG,S100B,SCN11A,SCN1A,SCN1 B,SCN2A,SCN2B,SCN3A,SCN3B,SCN4A,SCN4B,SCN5A,SCN7A,SCN8A,SCN9A,SDH A,SDHB,SDHC,SDHD,SEC14L2,SF3B3,SHBG,SIGMAR1,SLC8A1,SLCO1B3,SNOAL,SOA T1,SOAT2,SQR,SREBF1,STK17B,SULT2A1,SULT2B1,TCP14,TESA,TLR4,TM1468,TNF,T ONB,TOP2A,TRAPPC3,TRPA1,TRPM8,TRPV1,TRPV3,TTGR,UBA1,UGT3A1,UQCR10,U QCR11,UQCRB,UQCRC1,UQCRC2,UQCRFS1,UQCRH,UQCRQ,VDR,VLDLR,XYNY,XYN Z,YWHAE,72 CC-related protein,A2ML1,AARSD1,AATK,ABAT,ABCA2,ABCB1,ABCB11,ABCB7,ABCC1,ABCC2,A BCC4,ABCC5,ABCC6,ABCC9,ABCD1,ABCF2,ABCG2,ABHD5,ABRAXAS1,ACADVL,ACA N,ACAT1,ACD,ACE,ACHE,ACKR2,ACKR3,ACO1,ACP1,ACP5,ACR,ACSBG1,ACTA1,ACT A2,ACTB,ACTC1,ACTG1,ACTG2,ACTL6A,ACTL8,ACTN2,ACTN4,ACVR1,ACY1,ADA,AD AM10,ADAM12,ADAM15,ADAM17,ADAM28,ADAM9,ADAMTS10,ADAMTS2,ADAM TS5,ADAMTSL1,ADAR,ADARB2,ADARB2- AS1,ADCY10,ADCY8,ADCY9,ADCYAP1,ADCYAP1R1,ADGRE5,ADGRG6,ADGRL3,ADG RV1,ADH1B,ADH1C,ADIPOQ,ADIPOR1,ADIPOR2,ADM,ADORA1,ADORA2A,ADORA 2B,ADORA3,ADRA1A,ADRA1B,ADRA1D,ADRA2A,ADRA2B,ADRB1,ADRB2,ADRM1,A DSL,AEBP1,AFF2,AFM,AFP,AGA,AGER,AGK,AGO2,AGPAT2,AGPAT3,AGPAT4,AGPAT5, AGR2,AGRN,AGTPBP1,AGTR1,AHR,AHSG,AICDA,AIF1,AIF1L,AIFM1,AIM2,AIMP1,AIP, AJUBA,AK1,AK9,AKAP13,AKAP4,AKIP1,AKNA,AKR1B1,AKR1B10,AKR1C1,AKR1C2,A KR1C3,AKR1C4,AKT1,AKT2,AKT3,AKTIP,ALB,ALCAM,ALDH18A1,ALDH1A1,ALDH1A2 ,ALDH2,ALDOA,ALG1,ALG12,ALG14,ALG2,ALG3,ALG9,ALK,ALOX12,ALOXE3,ALPI,AL PL,ALPP,ALS2,ALX1,ALX3,AMACR,AMBN,AMBP,AMD1,AMELX,AMER1,AMER2,AMH, AMHR2,AMOTL1,AMPD1,AMPH,ANG,ANGPT1,ANGPT2,ANGPTL4,ANGPTL8,ANK3, ANKH,ANKRD1,ANKRD11,ANKRD13A,ANKRD13D,ANKRD18A,ANKRD2,ANKRD28, ANKRD40,ANKS1B,ANLN,ANO3,ANP32C,ANP32E,ANPEP,ANTXR1,ANTXR2,ANXA1, ANXA13,ANXA2,ANXA4,ANXA5,ANXA6,ANXA8,AOC1,AOC3,AOPEP,AP2A1,AP2A2, AP2B1,AP2M1,AP2S1,AP3D1,AP3M1,AP3S1,AP4E1,AP4S1,AP5Z1,APAF1,APC,APEX1 ,APH1A,APH1B,API5,APLN,APLNR,APLP1,APOA4,APOB,APOBEC1,APOBEC3A,APOB EC3A_B,APOBEC3B,APOBEC3C,APOBEC3D,APOBEC3F,APOBEC3G,APOBEC3H,APOC 3,APOE,APOH,APOM,APP,APRT,APTX,AQP1,AQP3,AQP4,AQP5,AQP7,AQP8,AR,ARE G,ARF1,ARHGAP17,ARHGAP22,ARHGAP26,ARHGAP8,ARHGEF2,ARHGEF37,ARID1A ,ARID1B,ARL11,ARL2,ARL6,ARL6IP1,ARMC1,ARMCX1,ARNT,ARRB2,ARRDC4,ARSA,A RSB,ARSE,ARSH,ARTN,ARVCF,ARX,ASCC2,ASCC3,ASCL1,ASGR2,ASPA,ASPHD1,ASP N,ASRGL1,ASXL1,ASXL2,ASXL3,ATAD2,ATAD3A,ATAD5,ATAT1,ATF3,ATF4,ATF5,ATF6, ATF6B,ATG12,ATIC,ATL1,ATM,ATP10B,ATP13A2,ATP1A2,ATP1A3,ATP2C1,ATP5PD,AT P6V1B2,ATP6V1G2,ATP7A,ATP7B,ATR,ATRAID,ATRX,ATXN1,ATXN2,ATXN3,ATXN7,A TXN8OS,AURKA,AURKB,AURKC,AVPR2,AXIN1,AXL,AZGP1,B2M,B3GALT4,B3GALT5,B 3GALT6,B3GAT1,B3GAT2,B3GAT3,B3GLCT,B3GNT2,B3GNT3,B4GALT3,B4GALT5,B4G ALT6,B4GALT7,BABAM1,BABAM2,BACE1,BAG1,BAG3,BAG6,BAIAP2- DT,BAK1,BANF1,BANP,BAP1,BARD1,BAX,BAZ1B,BBC3,BBIP1,BBS1,BBS10,BBS12,BBS 2,BBS4,BBS5,BBS7,BBS9,BCAP31,BCAR4,BCAS1,BCAS2,BCAT1,BCCIP,BCL10,BCL2,BC L2A1,BCL2L1,BCL2L10,BCL2L11,BCL2L14,BCL2L15,BCL2L2,BCL3,BCL6,BCOR,BCR,BC YRN1,BDNF,BDNF- AS,BECN1,BEST1,BFAR,BGLAP,BGN,BHLHE40,BHLHE41,BHMT,BICD2,BID,BIN1,BIRC2 ,BIRC3,BIRC5,BIRC6,BIRC7,BLACAT1,BLCAP,BLM,BLVRA,BLVRB,BLZF1,BMI1,BMP1,B MP2,BMP3,BMP4,BMP5,BMP6,BMP7,BMPER,BMPR1A,BMX,BNIP3,BOD1,BOK,BPI,B PTF,BRAF,BRAP,BRCA1,BRCA2,BRCC3,BRCD1,BRD4,BRD8,BRD9,BRF1,BRF2,BRI3BP,B RIP1,BRMS1,BRPF1,BRSK1,BRSK2,BSCL2,BSG,BSN,BTBD1,BTBD2,BTC,BTD,BTG2,BTG3 ,BTRC,BUB1B,BUB3,C10orf90,C12orf76,C15orf48,C19orf33,C1GALT1C1,C1QBP,C1RL ,C21orf91,C22orf46,C3,C3AR1,C3orf35,C4A,C4BPB,C5orf64,C6orf47,C8orf37,CA12, CA14,CA2,CA9,CAB39L,CACNA1A,CACNA1B,CACNA1S,CACNA2D2,CACUL1,CADM 1,CADM4,CALB1,CALB2,CALCA,CALCR,CALD1,CALM1,CALML3,CALR,CALU,CAMK2 G,CAMKK2,CAMP,CANT1,CANX,CAPN1,CAPN15,CAPN2,CAPN3,CAPN6,CAPZA1,CA PZA2,CARD8,CARD8- AS1,CARD9,CARNS1,CASC2,CASP1,CASP10,CASP14,CASP2,CASP3,CASP4,CASP5,C ASP6,CASP7,CASP8,CASP9,CASR,CAST,CASZ1,CAT,CATSPER1,CAV1,CAV2,CAV3,CAV IN1,CAVIN3,CBFB,CBL,CBLC,CBLN2,CBR4,CBS,CBX1,CBX3,CBX5,CBY1,CCAT1,CCAT2, CCDC106,CCDC107,CCDC134,CCDC22,CCDC26,CCDC34,CCDC50,CCDC7,CCDC8,CC DC88A,CCDC92,CCEPR,CCHCR1,CCK,CCL11,CCL19,CCL2,CCL20,CCL21,CCL3,CCL4,C CL4L1,CCL5,CCL7,CCL8,CCM2,CCN1,CCN2,CCN3,CCN4,CCN6,CCNA1,CCNA2,CCNB 1,CCND1,CCND3,CCNE1,CCNE2,CCNG1,CCNG2,CCNI,CCNL1,CCNQ,CCNT1,CCR1,CC R2,CCR3,CCR4,CCR5,CCR6,CCR7,CCT2,CD109,CD14,CD151,CD163,CD164,CD19,CD 1A,CD1B,CD1C,CD1D,CD1E,CD2,CD207,CD209,CD22,CD226,CD24,CD244,CD247,C D27,CD274,CD276,CD28,CD2AP,CD33,CD34,CD36,CD38,CD4,CD40,CD40LG,CD44,C D46,CD5,CD55,CD58,CD59,CD6,CD63,CD68,CD69,CD74,CD79A,CD80,CD81,CD82,C D83,CD86,CD8A,CD9,CD93,CD96,CDC14A,CDC20,CDC25A,CDC25B,CDC25C,CDC2 7,CDC37,CDC42,CDC42BPA,CDC45,CDC5L,CDC6,CDC7,CDC73,CDH1,CDH11,CDH1 3,CDH15,CDH17,CDH2,CDH20,CDH3,CDH8,CDIP1,CDK1,CDK10,CDK11B,CDK12,CD K16,CDK17,CDK18,CDK2,CDK20,CDK2AP1,CDK2AP2,CDK4,CDK5,CDK6,CDK7,CDK9, CDKN1A,CDKN1B,CDKN1C,CDKN2A,CDKN2B,CDKN2B- AS1,CDKN2C,CDKN3,CDT1,CDX2,CDX4,CDYL,CEACAM1,CEACAM3,CEACAM4,CEAC AM5,CEACAM6,CEACAM7,CEBPA,CEBPB,CEBPD,CEBPG,CELSR1,CEMIP,CENPU,CEP1 26,CEP290,CEP55,CEP68,CERCAM,CFAP36,CFD,CFH,CFI,CFL1,CFL2,CFLAR,CFM1,CFT R,CFTR- AS1,CGA,CGAS,CGB3,CGB5,CGB7,CGN,CH25H,CHAF1A,CHAF1B,CHAT,CHCHD10,C HD4,CHD7,CHEK1,CHEK2,CHFR,CHGA,CHGB,CHI3L1,CHIT1,CHKA,CHKB,CHL1,CHM ,CHMP3,CHN1,CHP1,CHRD,CHRM1,CHRM2,CHRM3,CHRNA1,CHRNA10,CHRNA3,C HRNA4,CHRNA5,CHRNB1,CHRNB2,CHRNB4,CHRND,CHRNE,CHRNG,CHST2,CHST3 ,CHST4,CHST6,CHSY1,CHUK,CIB1,CIITA,CILP,CINP,CIP2A,CISD2,CITED2,CIZ1,CKAP2, CKAP4,CKB,CLCA1,CLCA4,CLCF1,CLCN2,CLCN3,CLDN1,CLDN11,CLDN2,CLDN23,CL DN3,CLDN4,CLDN5,CLDN6,CLDN7,CLDN8,CLDN9,CLDND1,CLEC3B,CLEC4M,CLEC9 A,CLIC1,CLIP1,CLIP2,CLNS1A,CLPP,CLPX,CLSPN,CLSTN2,CLTCL1,CLU,CLUH,CMA1,C MKLR1,CMTM5,CNBP,CNC2,CNDP1,CNKSR1,CNN1,CNP,CNR1,CNR2,CNRIP1,CNTF, CNTN2,CNTNAP2,CNTNAP4,COG4,COL10A1,COL11A1,COL11A2,COL12A1,COL13A 1,COL15A1,COL17A1,COL18A1,COL1A1,COL1A2,COL25A1,COL27A1,COL2A1,COL3 A1,COL4A2,COL4A6,COL5A1,COL5A2,COL6A1,COL6A2,COL6A3,COL6A6,COL7A1,C OL8A2,COL9A1,COL9A2,COL9A3,COLEC10,COLEC11,COLGALT2,COLQ,COMP,COMT, COPS4,COPS5,COPS6,COQ8B,CORO2B,COX4I1,COX5A,CP,CPB1,CPE,CPEB1,CPLANE 1,CPLX1,CPNE8- AS1,CPOX,CPQ,CPSF2,CPT1A,CR1,CR2,CRABP1,CRABP2,CRAT,CRAT37,CRBN,CRCP,C REB1,CREB3,CREBBP,CRH,CRHBP,CRHR1,CRHR2,CRIP1,CRKL,CRLF1,CRNDE,CRNN,C RP,CRTAP,CRTC1,CRYAB,CRYGB,CS,CSF1,CSF1R,CSF2,CSF2RB,CSF3,CSF3R,CSH1,CSH 2,CSK,CSMD1,CSN2,CSNK1A1,CSNK2A1,CSNK2A2,CSNK2B,CSPP1,CSRNP1,CST6,C STA,CT45A5,CTAG1B,CTAG2,CTBP1,CTCF,CTCFL,CTDP1,CTDSPL,CTF1,CTHRC1,CTLA 4,CTNNA1,CTNNA3,CTNNB1,CTNNBIP1,CTNND1,CTNND2,CTSB,CTSD,CTSE,CTSF,C TSG,CTSH,CTSK,CTSL,CTSS,CTTN,CUEDC1,CUL1,CUL2,CUL4B,CUL5,CUL7,CUTA,CW C22,CX3CR1,CXADR,CXCL1,CXCL10,CXCL11,CXCL12,CXCL14,CXCL2,CXCL5,CXCL6,C XCL8,CXCL9,CXCR1,CXCR2,CXCR3,CXCR4,CXCR6,CYB5D2,CYBA,CYBB,CYCS,CYLD,C YP11A1,CYP19A1,CYP1A1,CYP1A2,CYP1B1,CYP21A1P,CYP21A2,CYP24A1,CYP26A1, CYP26B1,CYP27B1,CYP2A6,CYP2B6,CYP2C18,CYP2C19,CYP2C9,CYP2D6,CYP2E1,CY P2J2,CYP2R1,CYP3A4,CYP3A5,CYP3A7,CYP4F22,DAAM1,DAAM2,DAB2,DACT1,DAG 1,DANCR,DAO,DAPK1,DAPK3,DAXX,DAZL,DBH,DBNDD2,DBNL,DBX2,DCAF6,DCBL D2,DCC,DCK,DCLK1,DCLRE1C,DCN,DCT,DCTD,DCTN1,DCTN4,DCTPP1,DCUN1D1,D CX,DDB1,DDHD2,DDI2,DDIT3,DDR1,DDR2,DDRGK1,DDT,DDX18,DDX19B,DDX24,D DX39B,DDX39B- AS1,DDX3X,DDX4,DDX41,DDX47,DDX5,DDX50,DDX53,DDX58,DEDD2,DEFA1,DEFA3 ,DEFA4,DEFA5,DEFA6,DEFB1,DEFB103B,DEFB126,DEFB4A,DEK,DEPTOR,DERL1,DES, DFFA,DFFB,DGCR,DGCR10,DGCR11,DGCR12,DGCR2,DGCR5,DGCR6,DGCR6L,DGCR 8,DGCR9,DGLUCY,DGS2,DGUOK,DHCR24,DHCR7,DHDDS,DHDH,DHFR,DHODH,DH RS4,DHRS4L2,DHX16,DHX30,DIABLO,DICER1,DKK1,DKK3,DLC1,DLD,DLEU7- AS1,DLG1,DLG1- AS1,DLG3,DLG4,DLL1,DLL3,DLL4,DLX4,DMAP1,DMBT1,DMD,DMP1,DMPK,DMRTA2, DNA2,DNAAF1,DNAH17,DNAH8,DNAJA3,DNAJB6,DNAJC5,DNAJC6,DNAJC8,DNA JC9,DNAL4,DNASE1,DNASE1L3,DNER,DNM1,DNM2,DNM3,DNMT1,DNMT3A,DNM T3B,DNMT3L,DNTT,DOC2B,DOCK10,DOCK5,DOK7,DPAGT1,DPP4,DPY30,DPYD,DPY D- AS2,DPYSL5,DRD1,DRD2,DRD5,DROSHA,DSCAML1,DSE,DSG3,DSP,DSPP,DTNA,DTN B,DTX3L,DUPD1,DUSP1,DUSP11,DUSP19,DUSP3,DUSP6,DUSP7,DUT,DUX4,DUX4L1, DVL1,DVL1P1,DVL2,DVL3,DYM,DYNC1LI2,DYNLRB1,DYRK1A,DYRK1B,DYT13,DYT1 5,DYT2,DYT7,E2F1,E2F2,E2F3,E2F4,E2F5,E4F1,EBAG9,EBI3,EBP,ECE1,ECEL1,ECM1,ECT 2,EDC3,EDIL3,EDN1,EDN2,EDN3,EDNRA,EDNRB,EED,EEF1A1,EEF2,EFEMP1,EFEMP2, EFHD1,EFNA1,EFNB1,EFNB2,EFTUD2,EGF,EGFL8,EGFR,EGLN1,EGR1,EHMT1,EHMT2, EI24,EIF2AK2,EIF2AK3,EIF2S1,EIF3A,EIF3B,EIF3CL,EIF3E,EIF3F,EIF3I,EIF4A1,EIF4E,EIF4 EBP1,EIF4EBP3,EIF5,EIF5A,EIF5A2,EIF6,ELANE,ELAVL1,ELAVL3,ELAVL4,ELF1,ELF3,ELF 5,ELK1,ELK3,ELN,ELOB,ELOC,ELOVL1,ELOVL2,ELOVL2-
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0337275 A1 Pearlman Et Al
    US 20150337275A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0337275 A1 Pearlman et al. (43) Pub. Date: Nov. 26, 2015 (54) BOCONVERSION PROCESS FOR Publication Classification PRODUCING NYLON-7, NYLON-7.7 AND POLYESTERS (51) Int. C. CI2N 9/10 (2006.01) (71) Applicant: INVISTATECHNOLOGIES S.a.r.l., CI2P 7/40 (2006.01) St. Gallen (CH) CI2PI3/00 (2006.01) CI2PI3/04 (2006.01) (72) Inventors: Paul S. Pearlman, Thornton, PA (US); CI2P 13/02 (2006.01) Changlin Chen, Cleveland (GB); CI2N 9/16 (2006.01) Adriana L. Botes, Cleveland (GB); Alex CI2N 9/02 (2006.01) Van Eck Conradie, Cleveland (GB); CI2N 9/00 (2006.01) Benjamin D. Herzog, Wichita, KS (US) CI2P 7/44 (2006.01) CI2P I 7/10 (2006.01) (73) Assignee: INVISTATECHNOLOGIES S.a.r.l., (52) U.S. C. St. Gallen (CH) CPC. CI2N 9/13 (2013.01); C12P 7/44 (2013.01); CI2P 7/40 (2013.01); CI2P 13/005 (2013.01); (21) Appl. No.: 14/367,484 CI2P 17/10 (2013.01); CI2P 13/02 (2013.01); CI2N 9/16 (2013.01); CI2N 9/0008 (2013.01); (22) PCT Fled: Dec. 21, 2012 CI2N 9/93 (2013.01); CI2P I3/04 (2013.01); PCT NO.: PCT/US2012/071.472 CI2P 13/001 (2013.01); C12Y 102/0105 (86) (2013.01) S371 (c)(1), (2) Date: Jun. 20, 2014 (57) ABSTRACT Embodiments of the present invention relate to methods for Related U.S. Application Data the biosynthesis of di- or trifunctional C7 alkanes in the (60) Provisional application No.
    [Show full text]
  • Cell Death Via Lipid Peroxidation and Protein Aggregation Diseases
    biology Review Cell Death via Lipid Peroxidation and Protein Aggregation Diseases Katsuya Iuchi * , Tomoka Takai and Hisashi Hisatomi Department of Materials and Life Science, Faculty of Science and Technology, Seikei University, 3-3-1 Kichijojikitamachi, Musashino-shi, Tokyo 180-8633, Japan; [email protected] (T.T.); [email protected] (H.H.) * Correspondence: [email protected] or [email protected]; Tel.: +81-422-37-3523 Simple Summary: It is essential for cellular homeostasis that biomolecules, such as DNA, proteins, and lipids, function properly. Disturbance of redox homeostasis produces aberrant biomolecules, including oxidized lipids and misfolded proteins, which increase in cells. Aberrant biomolecules are removed by excellent cellular clearance systems. However, when excess aberrant biomolecules remain in the cell, they disrupt organelle and cellular functions, leading to cell death. These aberrant molecules aggregate and cause apoptotic and non-apoptotic cell death, leading to various protein aggregation diseases. Thus, we investigated the cell-death cross-linking between lipid peroxidation and protein aggregation. Abstract: Lipid peroxidation of cellular membranes is a complicated cellular event, and it is both the cause and result of various diseases, such as ischemia-reperfusion injury, neurodegenerative diseases, and atherosclerosis. Lipid peroxidation causes non-apoptotic cell death, which is associated with cell fate determination: survival or cell death. During the radical chain reaction of lipid peroxidation, Citation: Iuchi, K.; Takai, T.; various oxidized lipid products accumulate in cells, followed by organelle dysfunction and the Hisatomi, H. Cell Death via Lipid induction of non-apoptotic cell death. Highly reactive oxidized products from unsaturated fatty acids Peroxidation and Protein are detected under pathological conditions.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • Regulation of Mitochondrial and Nonmitochondrial Protein Turnover by the PINK1-Parkin Pathway
    Regulation of mitochondrial and nonmitochondrial protein turnover by the PINK1-Parkin pathway Evelyn S. Vincow A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2013 Reading Committee: Leo J. Pallanck, Chair Sandra M. Bajjalieh Michael J. MacCoss Program Authorized to Offer Degree: Neurobiology and Behavior © Copyright 2013 Evelyn S. Vincow University of Washington Abstract Regulation of mitochondrial and nonmitochondrial protein turnover by the PINK1-Parkin pathway Evelyn Sandra Vincow Chair of the Supervisory Committee: Associate Professor Leo J. Pallanck Genome Sciences The accumulation of damaged mitochondria has been proposed as a key factor in aging and in the pathogenesis of many common age-related diseases, including Parkinson disease (PD). Recently, in vitro studies of the PD-related proteins Parkin and PINK1 have found that these factors act in a common pathway to promote the selective autophagic degradation of damaged mitochondria (mitophagy). However, whether PINK1 and Parkin promote mitophagy in vivo is unknown. To address this question, I used a proteomic approach in Drosophila to study the effects of null mutations in parkin or PINK1 on mitochondrial protein turnover. The parkin null mutants showed a significant overall slowing of mitochondrial protein turnover, similar to but less severe than the slowing seen in autophagy-deficient Atg7 mutants, consistent with the model that Parkin acts upstream of Atg7 to promote mitophagy. By contrast, the turnover of many mitochondrial respiratory chain (RC) subunits showed greater impairment in parkin than in Atg7 mutants, and RC turnover was also selectively impaired in PINK1 mutants. These findings demonstrate that the PINK1-Parkin pathway promotes mitophagy in vivo and, unexpectedly, also promotes selective turnover of mitochondrial RC components.
    [Show full text]
  • An ACSL4 Hemizygous Intragenic Deletion in a Patient with Childhood Stroke
    Pediatric Neurology 100 (2019) 100e101 Contents lists available at ScienceDirect Pediatric Neurology journal homepage: www.elsevier.com/locate/pnu Clinical Letter An ACSL4 Hemizygous Intragenic Deletion in a Patient With Childhood Stroke Caitlin A. Chang, MD a, Julie Lauzon, MD, MHSc a, b, Adam Kirton, MD, MSc b, c, * Bob Argiropoulos, PhD a, b, d, a Department of Medical Genetics, Alberta Children's Hospital, Calgary, Alberta, Canada b Alberta Children's Hospital Research Institute for Child and Maternal Health, Alberta Children's Hospital, Calgary, Alberta, Canada c Department of Pediatrics and Clinical Neurosciences, Pediatric Neurology, Alberta Children's Hospital, Calgary, Alberta, Canada d Genetic Laboratory Services, Cytogenetics Laboratory, Alberta Children's Hospital, Calgary, Alberta, Canada article info Article history: Received 4 March 2019 Accepted 22 June 2019 Available online 28 June 2019 Keywords: Childhood stroke ACSL4 X-linked intellectual disability Ischemia Developmental delay We describe a male with a maternally inherited 9.75-kb intra- was present. Additional evaluation for stroke risk factors, including genic deletion of ACSL4. Fewer than 25 individuals have been re- lumbar puncture, echocardiogram, and examination of blood for fl ported with ACSL4-related X-linked intellectual disability (XLID). thrombophilia and in ammatory markers were negative. This individual highlights a unique presentation of ACSL4-related At three years, severe communication delays were evident. fi XLID and reveals additional pathways for investigation. Behavioral dif culties included frequent outbursts, irritability, and tantrums. There were no limitations in gross or fine motor func- Patient description tioning. At 4.5 years, he developed seizures characterized by eye deviation and automatisms.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Acot13 (NM 025790) Mouse Untagged Clone – MC203714 | Origene
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for MC203714 Acot13 (NM_025790) Mouse Untagged Clone Product data: Product Type: Expression Plasmids Product Name: Acot13 (NM_025790) Mouse Untagged Clone Tag: Tag Free Symbol: Acot13 Synonyms: 0610006O17Rik; Them2 Vector: PCMV6-Kan/Neo E. coli Selection: Kanamycin (25 ug/mL) Cell Selection: Neomycin Fully Sequenced ORF: >BC018165 TGATCATCTAGGACCAGGGCGACCGGGGCGCGCGATCCTTTCTCCCGAGCACGACGCGACACCGCCCGGG CTTGCAGACTTGACCTTCCACACCCTTGTCCTCTCACAAACGTCTCTTCCAGAGTTCACTCTCGCAGAGC CCAGACTCTTGCTTTGCGTCCACGATGAGCAGCATGACCCAGAACCTACGAGAAGTAATGAAGGTTATGT TCAAAGTTCCCGGTTTTGATAGAGTTTTGGAAAAGGTGACGCTTGTCTCGGCTGCTCCTGAGAAACTAAT CTGTGAGATGAAGGTGGAGGAGCAGCATACTAATAAGCTGGGTACGCTCCATGGAGGCTTGACAGCAACC TTAGTGGACAGCATCTCGACCATGGCTCTAATGTGCACAGAAAGAGGAGCACCCGGAGTCAGTGTGGACA TGAACATAACGTACATGTCACCTGCTAAGATAGGAGAAGAAATAGTGATCACAGCACACATTCTGAAGCA AGGAAAGACACTTGCATTTGCCTCAGTGGATCTGACCAACAAGACCACAGGAAAATTAATAGCACAAGGC AGACACACAAAACACCTGGGGAACTGAGAACAGCGGGAAGACCCGAAGAAGCCCAACAATGCCAAGTATG GTTTGTGAACAACTTTCTGAAATAAATTATCAAAACCAGAAAAAAAAAAAAAAAAAAAA Restriction Sites: RsrII-NotI ACCN: NM_025790 Insert Size: 423 bp OTI Disclaimer: Our molecular clone sequence data has been matched to the reference identifier above as a point of reference. Note that the complete sequence of our molecular clones may differ from the sequence published for this corresponding reference, e.g.,
    [Show full text]
  • Supplementary Material
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Neurol Neurosurg Psychiatry Page 1 / 45 SUPPLEMENTARY MATERIAL Appendix A1: Neuropsychological protocol. Appendix A2: Description of the four cases at the transitional stage. Table A1: Clinical status and center proportion in each batch. Table A2: Complete output from EdgeR. Table A3: List of the putative target genes. Table A4: Complete output from DIANA-miRPath v.3. Table A5: Comparison of studies investigating miRNAs from brain samples. Figure A1: Stratified nested cross-validation. Figure A2: Expression heatmap of miRNA signature. Figure A3: Bootstrapped ROC AUC scores. Figure A4: ROC AUC scores with 100 different fold splits. Figure A5: Presymptomatic subjects probability scores. Figure A6: Heatmap of the level of enrichment in KEGG pathways. Kmetzsch V, et al. J Neurol Neurosurg Psychiatry 2021; 92:485–493. doi: 10.1136/jnnp-2020-324647 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Neurol Neurosurg Psychiatry Appendix A1. Neuropsychological protocol The PREV-DEMALS cognitive evaluation included standardized neuropsychological tests to investigate all cognitive domains, and in particular frontal lobe functions. The scores were provided previously (Bertrand et al., 2018). Briefly, global cognitive efficiency was evaluated by means of Mini-Mental State Examination (MMSE) and Mattis Dementia Rating Scale (MDRS). Frontal executive functions were assessed with Frontal Assessment Battery (FAB), forward and backward digit spans, Trail Making Test part A and B (TMT-A and TMT-B), Wisconsin Card Sorting Test (WCST), and Symbol-Digit Modalities test.
    [Show full text]
  • By Submitted in Partial Satisfaction of the Requirements for Degree of in In
    BCL6 maintains thermogenic capacity of brown adipose tissue during dormancy by Vassily Kutyavin DISSERTATION Submitted in partial satisfaction of the requirements for degree of DOCTOR OF PHILOSOPHY in Biomedical Sciences in the GRADUATE DIVISION of the UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Approved: ______________________________________________________________________________Eric Verdin Chair ______________________________________________________________________________Ajay Chawla ______________________________________________________________________________Ethan Weiss ______________________________________________________________________________ ______________________________________________________________________________ Committee Members Copyright 2019 by Vassily Kutyavin ii Dedicated to everyone who has supported me during my scientific education iii Acknowledgements I'm very grateful to my thesis adviser, Ajay Chawla, for his mentorship and support during my dissertation work over the past five years. Throughout my time in his lab, I was always able to rely on his guidance, and his enthusiasm for science was a great source of motivation. Even when he was traveling, he could easily be reached for advice by phone or e- mail. I am particularly grateful for his help with writing the manuscript, which was probably the most challenging aspect of graduate school for me. I am also very grateful to him for helping me find a postdoctoral fellowship position. Ajay's inquisitive and fearless approach to science have been a great inspiration to me. In contrast to the majority of scientists who focus narrowly on a specific topic, Ajay pursued fundamental questions across a broad range of topics and was able to make tremendous contributions. My experience in his lab instilled in me a deep appreciation for thinking about the entire organism from an evolutionary perspective and focusing on the key questions that escape the attention of the larger scientific community. As I move forward in my scientific career, there is no doubt that I will rely on him as a role model.
    [Show full text]
  • Identification of ACSL4 As a Biomarker and Contributor of Ferroptosis In
    Identication of ACSL4 as a biomarker and contributor of ferroptosis in clear cell renal cell carcinoma na guo ( [email protected] ) Primary research Keywords: Acyl-CoA synthetase long-chain family member 4 (ACSL4), biomarker, ferroptosis, clear cell renal cell carcinoma (ccRCC) Posted Date: May 15th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-24079/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/17 Abstract Background ACSL4 has been reported to be related to tumor genesis and involved in the processes of ferroptosis. However, the expression levels and prognostic value of ACSL4 in clear cell renal cell carcinoma (ccRCC) remain unclear. Methods The Oncomine and TCGA databases were used to predict the expression of ACSL4 mRNA in ccRCC and its association with ccRCC prognosis. The expression levels of ACSL4 were determined in human RCC tissues by real-time PCR. Kaplan-Meier curves were used to analyze the diagnostic and prognostic signicance of ACSL4 in ccRCC. A ferroptosis inducer (erastin) was used to investigate the effects of ACSL4 on ferroptosis in ccRCC cell lines. Results The expression level of ACSL4 was signicantly down-regulated in ccRCC tissues (P < 0.001), which was consistent with the analysis of the Oncomine and TCGA database. Then, immunohistochemical results demonstrated that the ACSL4 was weak or not detected in ccRCC tissues than that in normal tissues. ACSL4 differential expression level was signicantly related to gender, ccRCC subtypes, nodal invasion, tumor grade and cancer stages (all P < 0.001). Survival analysis revealed that overall survival was favorable in ccRCC patients with ACSL4 high expression (P = 0.014).
    [Show full text]
  • Inflammatory Stimuli Induce Acyl-Coa Thioesterase 7 and Remodeling of Phospholipids Containing Unsaturated Long (C20)-Acyl Chains in Macrophages
    Supplemental Material can be found at: http://www.jlr.org/content/suppl/2017/04/17/jlr.M076489.DC1 .html Inflammatory stimuli induce acyl-CoA thioesterase 7 and remodeling of phospholipids containing unsaturated long (C20)-acyl chains in macrophages Valerie Z. Wall,*,† Shelley Barnhart,* Farah Kramer,* Jenny E. Kanter,* Anuradha Vivekanandan-Giri,§ Subramaniam Pennathur,§ Chiara Bolego,** Jessica M. Ellis,§§,*** Miguel A. Gijón,††† Michael J. Wolfgang,*** and Karin E. Bornfeldt1,*,† Department of Medicine,* Division of Metabolism, Endocrinology and Nutrition, and Department of Pathology,† UW Medicine Diabetes Institute, University of Washington, Seattle, WA; Department of Internal Medicine,§ University of Michigan, Ann Arbor, MI; Department of Pharmaceutical and Pharmacological Sciences,** University of Padova, Padova, Italy; Department of Nutrition Science,§§ Purdue University, West Lafayette, IN; Department of Biological Chemistry,*** Johns Hopkins University School of Medicine, Baltimore, MD; and Department of Pharmacology,††† University of Downloaded from Colorado Denver, Aurora, CO Abstract Acyl-CoA thioesterase 7 (ACOT7) is an intracel- containing unsaturated long (C20)-acyl chains in macro- lular enzyme that converts acyl-CoAs to FFAs. ACOT7 is in- phages, and, although ACOT7 has preferential thioesterase duced by lipopolysaccharide (LPS); thus, we investigated activity toward these lipid species, loss of ACOT7 has no ma- www.jlr.org downstream effects of LPS-induced induction of ACOT7 jor detrimental effect on macrophage inflammatory pheno- and its role in inflammatory settings in myeloid cells. Enzy- types.—Wall, V. Z., S. Barnhart, F. Kramer, J. E. Kanter, matic thioesterase activity assays in WT and ACOT7-deficient A. Vivekanandan-Giri, S. Pennathur, C. Bolego, J. M. Ellis, macrophage lysates indicated that endogenous ACOT7 con- M.
    [Show full text]